PT-141

PT-141, clinically known as bremelanotide, is a synthetic cyclic heptapeptide and melanocortin receptor agonist used to treat sexual dysfunction. Unlike traditional medications that target blood flow, PT-141 acts on the central nervous system to directly stimulate sexual desire and arousal.

Mechanism of Action
PT-141 functions by binding to and activating melanocortin receptors (specifically MC3R and MC4R) located in the hypothalamus and limbic system of the brain. This activation triggers downstream signaling cascades that increase dopamine release and modulate neural pathways associated with sexual motivation and reward. Because it targets the brain rather than the vascular system, it does not require the nitric oxide pathway used by drugs like Viagra (sildenafil) and can be effective for individuals who do not respond to PDE5 inhibitors.

FDA Approval and Indications
The U.S. Food and Drug Administration (FDA) approved PT-141 in June 2019 under the brand name Vyleesi. 

* Approved Use: It is indicated specifically for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. 
* Off-Label Use: It is frequently prescribed off-label for men suffering from erectile dysfunction (ED) and low libido, as well as for postmenopausal women, though these uses are not formally FDA-approved. 
Administration and Onset
PT-141 is designed for on-demand use rather than daily maintenance. 

* Route: The FDA-approved formulation (Vyleesi) is administered via subcutaneous injection using an auto-injector. 
 Compounded versions are also available as intranasal sprays. 
* Timing: It is typically administered 45 to 60 minutes before anticipated sexual activity. 
* Frequency: Usage is generally limited to no more than one dose per 24 hours and eight doses per month to prevent tolerance and side effects.